<?xml version="1.0" encoding="UTF-8"?>
<p>This work was supported by grant K01OD017242 from the Office of The Director, National Institutes of Health, grant AB15MN‐002 from the National Canine Cancer Foundation, a grant from the Masonic Cancer Center, University of Minnesota Sarcoma Translational Working Group, grant 1889‐G from the AKC Canine Health Foundation, the US Public Health Service Grant R01 CA36725 awarded by the NCI and the NIAID, DHHS, the Randy Shaver Cancer Research and Community Foundation, the Atwater Cancer Drug Development Award, a CETI Translational Award from the University of Minnesota Masonic Cancer Center, and a grant from GREYlong. The authors gratefully acknowledge generous support from the Angiosarcoma Awareness Foundation and donations to the Animal Cancer Care and Research Program of the University of Minnesota that helped support this project. The authors declare that patent „Reduction of EGFR therapeutic toxicity,„ related to this work has been filed by the Office of Technology Commercialization. Anivive Lifesciences has purchased the license for therapeutic use of eBAT for all non‐human species and applications.</p>
